JP2021504329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504329A5 JP2021504329A5 JP2020528072A JP2020528072A JP2021504329A5 JP 2021504329 A5 JP2021504329 A5 JP 2021504329A5 JP 2020528072 A JP2020528072 A JP 2020528072A JP 2020528072 A JP2020528072 A JP 2020528072A JP 2021504329 A5 JP2021504329 A5 JP 2021504329A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- optionally
- subject
- immune checkpoint
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 48
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 16
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 16
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 16
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 14
- 238000002560 therapeutic procedure Methods 0.000 claims 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 230000004913 activation Effects 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000035755 proliferation Effects 0.000 claims 4
- 230000003248 secreting effect Effects 0.000 claims 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 206010061818 Disease progression Diseases 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims 2
- 102000008166 Member 25 Tumor Necrosis Factor Receptors Human genes 0.000 claims 2
- 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims 2
- 101710187740 Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 101710165434 Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 238000003782 apoptosis assay Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 230000005522 programmed cell death Effects 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590785P | 2017-11-27 | 2017-11-27 | |
| US62/590,785 | 2017-11-27 | ||
| US201862635958P | 2018-02-27 | 2018-02-27 | |
| US62/635,958 | 2018-02-27 | ||
| PCT/US2018/062621 WO2019104327A1 (en) | 2017-11-27 | 2018-11-27 | Gp96-based cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504329A JP2021504329A (ja) | 2021-02-15 |
| JP2021504329A5 true JP2021504329A5 (enExample) | 2022-01-06 |
Family
ID=66631729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528072A Pending JP2021504329A (ja) | 2017-11-27 | 2018-11-27 | Ｇｐ９６ベースの癌療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210170025A1 (enExample) |
| EP (1) | EP3717003A4 (enExample) |
| JP (1) | JP2021504329A (enExample) |
| KR (1) | KR20200092964A (enExample) |
| CN (1) | CN111405909A (enExample) |
| AU (1) | AU2018373390A1 (enExample) |
| CA (1) | CA3083481A1 (enExample) |
| WO (1) | WO2019104327A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6744318B2 (ja) * | 2015-02-06 | 2020-08-26 | ヒート バイオロジクス，インコーポレイテッド | ワクチンおよび共刺激分子を共発現するベクター |
| WO2021113328A1 (en) | 2019-12-03 | 2021-06-10 | Neuvogen, Inc. | Tumor cell vaccines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2274001A4 (en) * | 2008-03-20 | 2012-08-01 | Univ Miami | VACCINATION WITH HEAT SHOCK PROTEIN GP96 AND APPLICATION METHOD THEREFOR |
| JP6744318B2 (ja) * | 2015-02-06 | 2020-08-26 | ヒート バイオロジクス，インコーポレイテッド | ワクチンおよび共刺激分子を共発現するベクター |
| KR20170138555A (ko) * | 2015-04-28 | 2017-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료 |
-
2018
- 2018-11-27 EP EP18881711.8A patent/EP3717003A4/en not_active Withdrawn
- 2018-11-27 JP JP2020528072A patent/JP2021504329A/ja active Pending
- 2018-11-27 KR KR1020207015128A patent/KR20200092964A/ko not_active Withdrawn
- 2018-11-27 CA CA3083481A patent/CA3083481A1/en active Pending
- 2018-11-27 AU AU2018373390A patent/AU2018373390A1/en not_active Abandoned
- 2018-11-27 US US16/763,867 patent/US20210170025A1/en not_active Abandoned
- 2018-11-27 WO PCT/US2018/062621 patent/WO2019104327A1/en not_active Ceased
- 2018-11-27 CN CN201880076245.9A patent/CN111405909A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Advances in cancer immunotherapy: historical perspectives, current developments, and future directions | |
| Gupta et al. | Immunotherapy: an alternative promising therapeutic approach against cancers | |
| Martin-Liberal et al. | The expanding role of immunotherapy | |
| Darragh et al. | Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment | |
| Zhang et al. | Current status and future directions of cancer immunotherapy | |
| Ventola | Cancer immunotherapy, part 1: current strategies and agents | |
| Zhu et al. | The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond | |
| Wennerberg et al. | Immune recognition of irradiated cancer cells | |
| Tongu et al. | Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo | |
| Salama et al. | Irradiation and immunotherapy: From concept to the clinic | |
| Ishihara et al. | Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment | |
| JP2020508329A5 (enExample) | ||
| JP2019501670A5 (enExample) | ||
| Rekers et al. | Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives | |
| Wang et al. | Radiotherapy as a new player in immuno-oncology | |
| Desbaillets et al. | Immunotherapy in glioblastoma: a clinical perspective | |
| Liu et al. | Immune-based therapy clinical trials in hepatocellular carcinoma | |
| Davis et al. | Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations | |
| Wolfson et al. | Stay on target: reengaging cancer vaccines in combination immunotherapy | |
| Murphy | Trends in cancer immunotherapy | |
| Xu et al. | Enhanced cellular therapy: revolutionizing adoptive cellular therapy | |
| Rafiq et al. | Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects | |
| JP2021504329A5 (enExample) | ||
| Yan et al. | OX40 as a novel target for the reversal of immune escape in colorectal cancer | |
| Mandala et al. | Rationale for new checkpoint inhibitor combinations in melanoma therapy |